Virtu Financial LLC Invests $354,000 in Revvity Inc. (NYSE:RVTY)

Virtu Financial LLC bought a new position in Revvity Inc. (NYSE:RVTY - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 3,344 shares of the company's stock, valued at approximately $354,000.

Other large investors have also recently bought and sold shares of the company. Nomura Holdings Inc. bought a new position in Revvity in the fourth quarter worth about $447,000. Wealth Enhancement Advisory Services LLC lifted its holdings in Revvity by 3.8% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 5,139 shares of the company's stock worth $544,000 after acquiring an additional 187 shares during the last quarter. Ritholtz Wealth Management bought a new position in Revvity in the first quarter worth about $210,000. Amalgamated Bank lifted its holdings in Revvity by 1.0% in the first quarter. Amalgamated Bank now owns 23,777 shares of the company's stock worth $2,516,000 after acquiring an additional 227 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in Revvity by 11.1% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 13,415 shares of the company's stock worth $1,417,000 after acquiring an additional 1,343 shares during the last quarter. Institutional investors own 86.65% of the company's stock.

Revvity Trading Down 1.6%

Revvity stock opened at $89.48 on Friday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 2.75 and a current ratio of 3.33. The firm has a market cap of $10.39 billion, a price-to-earnings ratio of 37.91, a price-to-earnings-growth ratio of 2.44 and a beta of 0.91. Revvity Inc. has a 1 year low of $85.12 and a 1 year high of $129.50. The firm's 50 day moving average price is $94.96 and its two-hundred day moving average price is $100.44.

Revvity (NYSE:RVTY - Get Free Report) last posted its quarterly earnings data on Monday, July 28th. The company reported $1.18 earnings per share for the quarter, topping the consensus estimate of $1.14 by $0.04. Revvity had a net margin of 10.19% and a return on equity of 7.66%. The firm had revenue of $720.28 million for the quarter, compared to analysts' expectations of $711.26 million. During the same period in the previous year, the company posted $1.22 EPS. The company's quarterly revenue was up 4.1% compared to the same quarter last year. On average, research analysts predict that Revvity Inc. will post 4.94 EPS for the current fiscal year.

Revvity Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, November 7th. Shareholders of record on Friday, October 17th will be given a dividend of $0.07 per share. This represents a $0.28 annualized dividend and a yield of 0.3%. The ex-dividend date is Friday, October 17th. Revvity's payout ratio is presently 11.86%.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. Raymond James Financial reaffirmed an "outperform" rating and set a $115.00 price target (down previously from $120.00) on shares of Revvity in a report on Tuesday, July 29th. Stifel Nicolaus cut their price target on Revvity from $120.00 to $110.00 and set a "hold" rating on the stock in a report on Tuesday, July 29th. Wall Street Zen cut Revvity from a "buy" rating to a "hold" rating in a report on Sunday, August 3rd. UBS Group raised Revvity from a "neutral" rating to a "buy" rating and cut their price target for the company from $145.00 to $115.00 in a report on Thursday, May 1st. Finally, Bank of America cut their price target on Revvity from $116.00 to $110.00 and set a "buy" rating on the stock in a report on Thursday, June 26th. Five research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $120.07.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.